v3.26.1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Summary of Operating Financial Results

The following table provides the operating financial results of the Biotechnology segment:

 

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

 

2026

 

 

2025

 

2026

 

 

2025

 

Total revenues

 

$

 

 

$

 

$

 

 

$

 

Significant segment expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

174

 

 

 

935

 

 

486

 

 

 

1,743

 

General and administrative expense

 

 

889

 

 

 

1,514

 

 

2,180

 

 

 

3,731

 

Loss (Gain) on disposal of assets

 

 

(9

)

 

 

60

 

 

28

 

 

 

86

 

Gain on lease termination

 

 

 

 

 

 

 

 

 

 

(5,974

)

Total operating expenses

 

 

(1,054

)

 

 

(2,509

)

 

(2,694

)

 

 

414

 

Interest and dividend income

 

 

11

 

 

 

56

 

 

11

 

 

 

88

 

Gain on settlement of accounts payable

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of contingent liability

 

 

(52

)

 

 

(159

)

 

(240

)

 

 

(295

)

Other income (expense)

 

 

(26

)

 

 

(9

)

 

(26

)

 

 

182

 

Total other income

 

 

(67

)

 

 

(112

)

 

(255

)

 

 

(25

)

Segment net (loss) income

 

$

(1,121

)

 

$

(2,621

)

$

(2,949

)

 

$

389